Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global
leader in cannabis research, cultivation, production, and
distribution, today announced that its medical cannabis division,
Tilray Medical, the global leader in medical cannabis,
enthusiastically welcomes the opening of the German medical
cannabis market and the positive paradigm shift in German drug
policy. Today’s landmark passage of the German Medical Cannabis Act
represents a significant step forward and puts public health in the
spotlight while providing patients with easier access to
high-quality cannabis medicines produced in Germany.
Tilray Medical's Chief Strategy Officer and Head
of International Denise Faltischek comments: "The decision to open
up the previously limited German medical cannabis market is an
important step that will allow patients and physicians to explore
effective treatment options tailored to individual needs.
Facilitating access to the highest quality cannabis medicines
through the new Medical Cannabis Act, produced in Germany, will
help to improve patient care and provide patients with a wider
range of treatment options."
Tilray Medical looks forward to working with
numerous partners to utilize the production capacity at Tilray’s
state of the art Neumünster site, which is one of only three
cannabis cultivation facilities located in Germany, in order to
ensure that patients have improved access to the highest quality
cannabis medicines grown in Germany.
As a leader in the field of medical cannabis
research and production, Tilray Medical strongly believes that
these developments will have a positive impact on the health and
well-being of many patients in Germany. We look forward to
exploring the path opended by the German government and all
stakeholders in promoting improved access to medical cannabis, and
the opportunity to optimize care for our patients.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering
dignity for patients in need through safe and reliable access to a
global portfolio of medical cannabis brands, including Tilray,
Aphria, Broken Coast, Symbios, and Navcora. Tilray Medical grew
from being one of the first companies to become an approved
licensed producer of medical cannabis in Canada to building the
first GMP-certified cannabis production facilities in Europe, first
in Portugal and later in Germany. Today, Tilray Medical is one of
the biggest suppliers of medical cannabis brands to patients,
physicians, hospitals, pharmacies, researchers, and governments, in
over 20 countries and across five continents.
Further information can also be found at
www.tilraymedical.de
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a
leading global cannabis lifestyle and consumer packaged goods
company with operations in Canada, the United States, Europe,
Australia, and Latin America that is changing people's lives for
the better – one person at a time – by inspiring and empowering a
worldwide community to live their very best life, enhanced by
moments of connection and wellbeing. Tilray’s mission is to be the
most responsible, trusted and market leading cannabis consumer
products company in the world with a portfolio of innovative,
high-quality, and beloved brands that address the needs of the
consumers, customers, and patients we serve. A pioneer in cannabis
research, cultivation, and distribution, Tilray’s unprecedented
production platform supports over 20 brands in over 20 countries,
including comprehensive cannabis offerings, hemp-based foods, and
craft beverages.
For more information on how we open a world of wellbeing, visit,
Tilray.com and follow @Tilray on all social platforms.
Forward-Looking Statements
Certain statements in this communication that are not historical
facts constitute forward-looking information or forward-looking
statements (together, “forward-looking statements”) under Canadian
securities laws and within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, that are intended to
be subject to the “safe harbor” created by those sections and other
applicable laws. Forward-looking statements can be identified by
words such as “forecast,” “future,” “should,” “could,” “enable,”
“potential,” “contemplate,” “believe,” “anticipate,” “estimate,”
“plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and
the negative of these terms or similar expressions, although not
all forward-looking statements contain these identifying words.
Certain material factors, estimates, goals, projections, or
assumptions were used in drawing the conclusions contained in the
forward-looking statements throughout this communication.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses, or current
expectations concerning, among other things, the Company’s ability
to commercialize new and innovative products worldwide. Many
factors could cause actual results, performance, or achievement to
be materially different from any forward-looking statements, and
other risks and uncertainties not presently known to the Company or
that the Company deems immaterial could also cause actual results
or events to differ materially from those expressed in the
forward-looking statements contained herein. For a more detailed
discussion of these risks and other factors, see the most recently
filed annual information form of Tilray and the Annual Report on
Form 10-K (and other periodic reports filed with the SEC) of Tilray
made with the SEC and available on EDGAR. The forward-looking
statements included in this communication are made as of the date
of this communication and the Company does not undertake any
obligation to publicly update such forward-looking statements to
reflect new information, subsequent events, or otherwise unless
required by applicable securities laws.
For further information: Media:
Berrin Noorata, news@tilray.com Investors: Raphael Gross,
+1-203-682-8253, Raphael.Gross@icrinc.com
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
From Apr 2023 to Apr 2024